HDAC inhibitors with PD-1 blockade: a promising strategy for treatment of multiple cancer types?
Author:
Affiliation:
1. Departments of Immunology & Thoracic Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA
2. Department of Thoracic Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA
Publisher
Future Medicine Ltd
Subject
Cancer Research,Genetics
Link
https://www.futuremedicine.com/doi/pdf/10.2217/epi-2016-0066
Reference20 articles.
1. Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
2. Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
3. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
4. Big opportunities for small molecules in immuno-oncology
5. Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance
Cited by 22 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Cancer plasticity in therapy resistance: Mechanisms and novel strategies;Drug Resistance Updates;2024-09
2. Histone deacetylase inhibitor and PD‑1 blockade synergistically inhibit B‑cell lymphoma progression in mice model by promoting T‑cell infiltration and apoptosis;Oncology Reports;2024-08-07
3. Cancer Epigenetics;Handbook of Epigenetics;2023
4. DNA and histone modifications as potent diagnostic and therapeutic targets to advance non-small cell lung cancer management from the perspective of 3P medicine;EPMA Journal;2022-11-02
5. A Therapeutic Perspective of HDAC8 in Different Diseases: An Overview of Selective Inhibitors;International Journal of Molecular Sciences;2022-09-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3